Diagnostic Challenge of Immune Checkpoint Inhibitor-Induced Hypophysitis in Patient With Melanoma. (PubMed, Fed Pract) - Sep 10, 2026 - "A 73-year-old male with a history of metastatic melanoma who had received 5 cycles of pembrolizumab (anti-PD-1) and 2 cycles of combination ICI therapy with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1) presented to a US Department of Veterans Affairs medical center 3 weeks after completing his second cycle of therapy with fatigue, headache, and hyponatremia...The patient was treated with intravenous hydrocortisone for suspected central adrenal insufficiency...ICI-induced hypophysitis is irreversible, can impact quality of life, and requires maintenance replacement therapy. As ICI therapies become more prevalent in the treatment of solid cancers, it is expected that clinicians will see more cases of ICI-related irAEs, such as hypophysitis, and must become comfortable with diagnosis, treatment, and management."
Checkpoint inhibition • Journal • Cardiovascular • Endocrine Disorders • Fatigue • Heart Failure • Immunology • Melanoma • Nephrology • Oncology • Pain • Renal Disease • Solid Tumor
|
|
Alexandra Rusz; Imran Baig; Melanie Kirk; Viraj Modi; Woo Jin Seog
|